Supporting Figure S2 : PAC-1/1541B combinations induce dose-dependent rapid and dramatic procaspase-3 activation in A549 cancer cells in culture. Cancer cell lines were treated with PAC-1 (30 µM), 1541B (7.5, 10, 12.5 µM), or PAC-1 + 1541B. Cells were lysed at various time points, and caspase-3/-7 activity of the lysates was evaluated with the fluorogenic Ac-DEVD-AFC substrate. Error bars represent the s.e.m. of three replicates. Table S1 . MTD studies of 1541B (formulated at 0.5 mg/ml in HPCD), administered by IP injection in female C57BL/6 mice (3 mice per group). Mice were treated daily with escalating doses of compound and monitored for signs of toxicity. Table 1 . MTD studies of 1541B (formulated at 0.5 mg/ml in HPβCD), administered by intraperitoneal injection in female C57BL/6 mice. Table S2 : MTD studies of 1541B in combination with PAC-1, compounds administered sequentially. The determined MTD of 1541B of 20 mg/kg and the known MTD of daily PAC-1 treatments (200 mg/kg) were used as the base unit for a modified dose escalation study. Mice were treated with the appropriate dose of PAC-1 one hour prior to treatment with 1541B. Mice were monitored for signs of toxicity. Table 2 . MTD studies of PAC-1 (formulated at 12.5 mg/ml in HPβCD) and 1541B (formulated at 0.5 mg/ml in HPβCD), administered by intraperitoneal injection in female C57BL/6 mice. PAC-1 was given 1 hour before 1541B treatment.
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